Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Total Non-Current Liabilities (2016 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Total Non-Current Liabilities for 14 consecutive years, with $43.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Non-Current Liabilities fell 22.45% year-over-year to $43.9 million, compared with a TTM value of $43.9 million through Sep 2025, down 22.45%, and an annual FY2024 reading of $43.9 million, up 41.92% over the prior year.
  • Total Non-Current Liabilities was $43.9 million for Q3 2025 at Fennec Pharmaceuticals, roughly flat from $43.9 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $56.8 million in Q2 2024 and bottomed at $4.0 million in Q2 2022.
  • Average Total Non-Current Liabilities over 5 years is $30.6 million, with a median of $25.6 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities skyrocketed 536.24% in 2023, then decreased 22.63% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $5.0 million in 2021, then surged by 399.28% to $24.9 million in 2022, then increased by 24.23% to $30.9 million in 2023, then surged by 41.92% to $43.9 million in 2024, then increased by 0.09% to $43.9 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for FENC at $43.9 million in Q3 2025, $43.9 million in Q2 2025, and $43.9 million in Q1 2025.